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Abstract
Adaptation is likely to be an important determinant of the success of many pathogens, for example when colonizing a new
host species, when challenged by antibiotic treatment, or in governing the establishment and progress of long-term chronic
infection. Yet, the genomic basis of adaptation is poorly understood in general, and for pathogens in particular. We
investigated the genetics of adaptation to cystic fibrosis-like culture conditions in the presence and absence of
fluoroquinolone antibiotics using the opportunistic pathogen Pseudomonas aeruginosa. Whole-genome sequencing of
experimentally evolved isolates revealed parallel evolution at a handful of known antibiotic resistance genes. While the level
of antibiotic resistance was largely determined by these known resistance genes, the costs of resistance were instead
attributable to a number of mutations that were specific to individual experimental isolates. Notably, stereotypical
quinolone resistance mutations in DNA gyrase often co-occurred with other mutations that, together, conferred high levels
of resistance but no consistent cost of resistance. This result may explain why these mutations are so prevalent in clinical
quinolone-resistant isolates. In addition, genes involved in cyclic-di-GMP signalling were repeatedly mutated in populations
evolved in viscous culture media, suggesting a shared mechanism of adaptation to this CF–like growth environment.
Experimental evolutionary approaches to understanding pathogen adaptation should provide an important complement to
studies of the evolution of clinical isolates.
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Introduction
In the mid-1800’s, Louis Pasteur advised microbiologists to think
of the human body as a ‘‘culture vessel’’ for microbes, in the context
of understanding immunity [1]. Pasteur’s approach has been revised
and updated several times [2,3], with a recent review encouraging
researchers to be attentive to the effects of different in vivo carbon
sources on bacterial metabolism and physiology [2]. Pasteur’s
advice is particularly relevant for an understanding of the evolution
of disease-causing microbes. Natural selection may be imposed by
the particular nutritional and metabolic resources available in a
given tissue, the innate and adaptive immune systems, and, in the
past 80 or so years, by antibiotics or anti-virals. Many pathogens –
particularly opportunistic pathogens, emerging pathogens, and
microbes causing chronic disease – are faced with a novel and
hostile growth environment to which they must adapt or face
extinction. Colonization and establishment of an infection in a new
host or host species can thus be interpreted as a specific instance of a
more general process of adaptation to a novel environment.
Understanding adaptive processes in pathogen populations, and
in particular characterizing the variety of genetic routes to
adaptation, is important for developing effective treatment
strategies. Take as an example the management of antibiotic
resistance. Resistance is often thought to be costly, in the sense that
resistant strains should be less fit than susceptible strains in the
absence of antibiotic. If so, then attempts to reduce the frequency
of resistance in patient populations by stopping the use of an
antibiotic should afford sensitive strains an advantage, and so
prolong the utility of an antibiotic for treatment. Antibiotic
cessation has met with mixed success (e.g., [4–6]), however, either
because some resistance mutations actually pay little or no cost, or
because second site mutations that restore fitness without
compromising resistance are common. The management of
antibiotic resistance in patient populations depends crucially on
which of these two mechanisms is more often responsible for the
persistence of resistance.
The last 15 years have seen a number of studies of in vivo
genome evolution in select pathogens, primarily viruses (e.g., [7,8])
and bacteria (e.g., [9,10]), that shed vital insight onto the genetic
changes that occur during epidemics or chronic infections. The
importance of these changes for pathogen fitness in a host can be
difficult to ascertain, however, because it is rarely possible to
establish with certainty that the observed mutations are adaptive,
since some neutral or deleterious mutations may accumulate
through drift or by hitchhiking with adaptive mutations. More-
over, it can be difficult to obtain sufficient in vivo samples to ask
questions about the repeatability of in vivo evolution – that is, how
often pathogens take the same adaptive routes in independent
patients or populations.
For these reasons we have turned to a complementary
approach, laboratory selection experiments, to provide an
understanding of the broad patterns and principles of pathogen
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evolution. In a typical microbial experimental evolution protocol,
many populations are founded from a single genotype, and are
propagated serially or in a chemostat for tens, hundreds, or
thousands of generations (reviewed in [11]). By maintaining
multiple replicate populations in each of two or more environ-
ments (e.g., antibiotic treated vs. not antibiotic treated), the effects
of a treatment can be systematically investigated in a manner that
is often inaccessible with in vivo samples. Experimental evolution
has by now a rich history in studying basic evolutionary processes
(e.g., [11–14] for reviews), as well as more applied topics such as
the evolution of antibiotic resistance [15,16] and of virulence [7].
In addition, experimental evolution has significant potential as an
investigative tool for elucidating basic biological processes [17,18].
With the development of technologies that allow the rapid and
affordable sequencing of entire bacterial genomes, an increasing
number of studies have sought to describe the genomic basis of
laboratory adaptation (reviewed in [19]).
Here we use a combination of experimental evolution and
whole-genome sequencing (WGS) to investigate the initial stages of
pathogen adaptation using the bacterium Pseudomonas aeruginosa.
This gram-negative bacterium is widely distributed in nature [20],
and is an important opportunistic pathogen. P. aeruginosa can cause
acute infections of wounds, burns and of lungs, and is frequently
implicated in nosocomial infections. Moreover, P. aeruginosa is an
important pathogen of individuals with cystic fibrosis (CF), with
approximately 60–70% of Canadian adults with CF harbouring
this bacterium [21]. P. aeruginosa chronically infects the CF lung,
and once the infection is established, it is virtually impossible to
eradicate: Intensive antibiotic regimens are effective at reducing
symptoms, but almost never succeed in clearing the infection
entirely.
P. aeruginosa populations that have persisted for long periods of
time in the lungs of individuals with CF show characteristic
signatures of adaptation to this novel culture environment. Recent
studies have documented patterns of parallel evolution at the level
of phenotype, gene expression, and genotype [10,22–25], indicat-
ing repeatable patterns of long-term adaptation to the CF lung.
For example, CF lung sputum is highly viscous, and P. aeruginosa
typically grows as an unattached biofilm, or microcolony, in this
environment [26]. While environmental isolates of P. aeruginosa are
motile, long-term CF colonists show evidence of adaptation to the
sessile lifestyle of the microcolony, including reduced motility, and
a morphological shift to small colony variants (SCVs) on agar
plates [27,28]. Increased intracellular levels of cyclic di-GMP are
thought to be important for this adaptive shift [27–29], but the
causative mutations have yet to be fully elucidated. Other
characteristic changes include mutations associated with reduced
virulence, presumably to avoid detection by the host immune
system, and increased small molecule efflux that can afford
resistance to antibiotics commonly used with CF patients [10].
Given evidence of long-term adaptation during chronic
infection in P. aeruginosa, we have examined the genomic basis of
adaptation to CF-like culture conditions and to fluoroquinolone
antibiotics through WGS of experimentally evolved P. aeruginosa
isolates. Our primary aim is to describe the genetic changes
underlying adaptation to this novel environment, and to ask how
repeatable these changes are. In addition, we also investigate the
genetic architecture of the costs of resistance: When antibiotic
resistance evolves, how often is it costly, and what mutations
underlie those costs? Our data allow us to quantify the nature and
extent of parallel genomic evolution and, in so doing, provide a
unique view of the variety of genetic routes taken during
adaptation to a medically relevant novel environment.
Results/Discussion
Adaptation to culture environments and to ciprofloxacin
In our selection experiment, we manipulated the bacterial
growth environment so as to resemble the CF lung with respect to
nutrition, viscosity, and antibiotic treatment. Populations of P.
aeruginosa were evolved in synthetic cystic fibrosis sputum (scfm;
[30]) for 8 days in the presence or absence of ciprofloxacin (Cip)
and/or mucin. Scfm is a defined medium resembling the
nutritional environment of the CF lung [30]. Ciprofloxacin was
added at a concentration comparable to that found in the sputum
of CF patients (1 ug/ml; [31]). Mucin increases the viscosity of the
culture medium, and is meant to mimic the high viscosity of CF
sputum [32,33]. In vivo, viscous sputum is thought to support the
growth of P. aeruginosa in unattached biofilms, called microcolonies
[26,34], and similar structures have been observed in mucin-
supplemented media (e.g., [32,33]). Mucin was added at 10 g/L.
Mucin may also act as a source of nutrients. The selection
experiment comprised a fully factorial design giving four selection
environments: scfm alone, scfm+Cip, scfm+mucin, and scfm+mu-
cin+Cip; 12 replicate populations were propagated in each
environment. Populations were maintained in a 37uC shaking
incubator in 1.5 ml of medium, with serial transfer at a 1:61
dilution every 24 hours, with approximately 5.9 generations of
growth per day (47.5 generations in total).
Since the CF lung – and by extension laboratory media
designed to mimic aspects of the CF lung – is a unique growth
environment for bacteria, our evolved P. aeruginosa populations are
expected to adapt to this novel habitat. Adaptation is also expected
to occur in response to ciprofloxacin through the selection of
mutations conferring resistance. Our experimental design allows
us to disentangle these two effects, with fitness in the absence of
antibiotic serving as a measure of adaptation to the growth
medium, and changes in resistance to ciprofloxacin indicating
adaptation to the presence of this antibiotic. Since populations
may harbour extensive genetic and phenotypic variation, we
measured resistance and fitness for evolved populations, as well as
for a single genotype isolated from each population.
As expected, antibiotic resistance evolved in the presence of
ciprofloxacin at both the population and genotype levels (Figure 1).
Populations evolved in the presence of Cip showed a 32-fold to
192-fold increase in minimal inhibitory concentration (MIC) over
the ancestral genotype Pa14, whereas those evolved in the absence
of Cip increased MIC by no more than 2-fold. Single genotypes
isolated from each population gave similar results: genotypes
Author Summary
Pathogens face a hostile and often novel environment
when infecting a new host, and adaptation to this
environment can be critical to a pathogen’s survival. The
genetic basis of pathogen adaptation is in turn important
for treatment, since the consistency with which therapies
succeed may depend on the extent to which a pathogen
adapts via the same routes in different patients. In this
study, we investigate adaptation of the bacterium Pseu-
domonas aeruginosa to laboratory conditions that resem-
ble the lungs of cystic fibrosis patients and to quinolone
antibiotics. We find that a handful of genes and genetic
pathways are repeatedly involved in adaptation to each
condition. Nonetheless, other, less common mutations can
play important roles in determining fitness, complicating
strategies aimed at reducing the prevalence of antibiotic
resistance.
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evolved in Cip had MICs ranging from 32-fold to 192-fold greater
than the ancestor.
To detect adaptation to the growth medium we assayed the
fitness of evolved populations and genotypes in the absence of
antibiotic using direct, head-to-head competitions against Pa14
(see Materials and Methods). We interpret the population-level
assays as a measure of the extent of adaptation achieved, since
these reflect the average increase in fitness of all genotypes present
at the end of the experiment. The single-genotype assays provide a
measure of adaptation for the same genotypes we have sequenced
(see below). Note that there will be a close correspondence
between measures of fitness at the population and single-genotype
levels only if the population is genetically uniform, as expected
under a model of periodic strong selection. If, however, the
population is genetically polymorphic, perhaps because mutation
supply rates (the product of population size, N, and mutation rate,
u) are high or distinct genotypes are maintained by negative
frequency dependent selection, then adaptation detected at the
level of the population may not be accurately predicted by assays
of fitness from single genotypes.
Our results are shown in Figure 2, where the dark bars
represent the extent of adaptation by entire populations and the
light bars adaptation by single genotypes. Evolved populations
adapted to the growth medium without antibiotic only when
mucin was present in the medium. In the absence of mucin, there
was either no response to selection (scfm) or a significant cost to
adaptation to Cip (scfm+Cip; ANOVA: P=2.961025; Table 1).
Thus, the presence of mucin in the environment affords a greater
opportunity for rapid adaptation.
The single genotype fitness data are more mixed and do not
correspond well with the population-level fitness assays (Figure S1),
suggesting the presence of substantial amounts of genetic diversity
within populations. We saw no consistent effect of mucin or of
antibiotic on adaptation to the growth medium, as indicated by a
lack of main effect for either of these factors by ANOVA (Table 1).
There was, however, a significant interaction between medium
and antibiotic (ANOVA: P=0.013; Table 1), reflecting the
observation that scfm+Cip-evolved genotypes were on average
more fit than the ancestor (mean relative fitness w=1.09/
generation), whereas the scfm+mucin+Cip-evolved genotypes were
on average less fit than the ancestor (mean w=0.86/generation).
This interpretation is reinforced by a lack of correlation between
genotypes and populations for MIC, for which there was little
correspondence between the level of resistance (Figure S2).
Taken together, these results suggest two important conclusions
about short-term adaptation to a CF lung-like environment: (1)
adaptation does occur, and it is driven primarily by the presence of
mucin; and (2) substantial genetic diversity is likely to be present in
evolving populations shortly after colonization, a result consistent
with the observation that P. aeruginosa isolates from CF patients can
often be highly diverse [10,35,36].
Whole-genome sequencing of evolved genotypes
In order to gain insight into the genetic causes of adaptation, we
sequenced the genomes of the pure genotypes assayed above, with
one genotype sampled from each of the 48 evolved populations
(that is, a single genotype from each population evolved in scfm
alone, scfm+ciprofloxacin, scfm+mucin, and scfm+mucin+cipro-
floxacin), as well as of our laboratory’s isolate of the ancestral
strain Pa14. We obtained a median coverage of ,56-fold per
genotype (mean= 55.5; range 31.8–85.4) on the Illumina plat-
form, using 75-bp paired-end reads. Given that a previous study
suggested that 15–20-fold coverage is sufficient for identifying a
modest number of mutations in laboratory selected microbial
strains [37], the depth of coverage we achieved should allow us to
identify all SNPs and small indels throughout most of the genome.
In addition, the sequenced genomes were surveyed for large
insertion/deletion events, such as mobile element insertions or
Figure 1. Minimum inhibitory concentration (MIC) to ciprofloxacin for each of 48 experimentally evolved populations (‘‘pop’’) or
single gentoypes (‘‘single’’). Populations were evolved in the presence (black) or absence (grey) of 1 mg/ml ciprofloxacin for 8 days (,50
generations). Two different media were used, as indicated on the X-axis.
doi:10.1371/journal.pgen.1002928.g001
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excisions. We were unable to survey ,0.53% of the genome in
each strain due to low coverage (defined as less than five reads
covering a given nucleotide).
Across all 48 evolved strains, we identified 98 SNPs and small
indels (mean 2.04/strain) not present in the ancestor (Table S1 lists
all mutations and their predicted functional consequences). These
mutations represented 77 unique changes, affecting a total of 44
genes and 4 putatively intergenic regions. No large insertion/
deletion events were found using BRESEQ [38]. Two genotypes,
both isolated from the scfm+mucin+Cip treatment, bore lesions in
mutS and were thus likely mutator strains, an inference supported
by the relatively high number of mutations found in these strains
(one carried 30 mutations, and the other carried 4, representing
the 1st and 3rd ranked genotypes in terms of number of
mutations), as well as by an extreme transition:transversion bias
amongst point mutations (all 26 point mutations found in these
two strains were transitions), which is characteristic of mutS
mutants [39]. If these putative mutator strains are omitted, we
found 64 mutations (44 unique changes) affecting 20 genes and 1
intergenic region (Figure S3). These mutations included 41 point
mutations and 23 insertion/deletions (indels).
Genotypes evolved in the presence of ciprofloxacin or mucin
carried more mutations on average than genotypes not evolved
with antibiotic (Figure 3). Interestingly, genotypes from the most
complex environment, containing both ciprofloxacin and mucin,
carried more mutations than any other environment, on average.
This result is broadly consistent with the idea that the number of
mutations involved in adaptation increases with the number of
distinct niche dimensions in the environment, an interpretation
supported by both antibiotic and presence/absence of mucin
being significant predictors of the number of mutations identified
(ANOVA, mutators excluded; medium: F=8.6, P=0.005; anti-
biotic: F=111.8, P=2610213).
Previous studies of the genomic basis of adaptation in
experimentally evolved bacterial populations have detected, on
average, 1.07 mutations/100 generations (range: 0.09–3.94; [40]).
The numbers of mutations observed after ,48 generations in our
antibiotic-evolved genotypes (mean 2.1 and 2.6 in scfm and
scfm+mucin, respectively) are thus substantially higher than
observed in previous studies. This difference probably reflects
the strong selection imposed by antibiotic treatment, as opposed to
the weaker selection commonly observed in resource-adaptation
experiments, combined with sufficiently large population sizes to
ensure the availability of multiple beneficial mutations in the same
population or even the same genome [41]. Notably, the rate of
accumulation of adaptive mutations observed here is consistent
with theoretical models of substitution under strong selection that
show expected fixation times of 50 generations or less for
mutations with large selection coefficients (see Figure S4 from
[42]). At the opposite end of the spectrum, very few mutations
were detected in our scfm populations, with 10 genotypes bearing
no mutations, and 2 genotypes carrying a single mutation each.
This result is consistent with the lack of fitness response observed
above (Figure 2) and is broadly consistent with the theoretical
expectation under neutrality, whereby the expected fraction of
6.5 Mb genomes with zero mutations after 48 generations should
be 0.73–0.97, depending on the per base pair mutation rate (taken
as 1610210 to 161029 for these estimates; [43]).
Broad patterns of nucleotide variability suggest that natural
selection has played an important role in shaping the observed
spectrum of mutations. Amongst the 41 point mutations observed
Figure 2. Competitive fitness of experimentally evolved populations (dark bars) or single genotypes (light bars). Fitness was
measured in the absence of antibiotic via direct competitions with a lacZ marked ancestral strain (Pa14). The height of each bar indicates mean fitness
for 12 evolved populations (genotypes), with the error bar giving +/21 SE. Competitions were carried out in scfm for populations (genotypes)
evolved in scfm or in scfm+ciprofloxacin, and in scfm+mucin for populations (genotypes) evolved in scfm+mucin or in scfm+mucin+ciprofloxacin.
Fitness below one indicates low fitness relative to the ancestor, while fitness above one indicates an overall benefit in the absence of antibiotic.
doi:10.1371/journal.pgen.1002928.g002
Table 1. Effects of selection environment on fitness in the
absence of antibiotic.
Population Single genotypes
Factor F-value P-value F-value P-value
Medium 21.76 2.8961025 2.03 0.16
Antibiotic 0.76 0.39 0.01 0.93
Medium*antibiotic 0.19 0.66 6.72 0.013
doi:10.1371/journal.pgen.1002928.t001
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in the non-mutator strains, 39 were nonsynonymous, 1 was
synonymous, and 1 was putatively non-coding. Since approxi-
mately 1/3 of random coding changes are expected to be
synonymous, the lack of synonymous mutations is consistent with
natural selection favouring a substantial fraction of the observed
mutations in the non-mutators. Using a randomization approach
(see Materials and Methods), we find that both the excess of non-
synonymous mutations, and the paucity of synonymous mutations,
are highly significant (Figure S4; P,0.0005). By contrast, many
more synonymous mutations were observed in the putative
mutator strains, with 15 non-synonymous, 8 synonymous, 8 genic
frame-shifts, and 3 intergenic mutations identified in the 2 putative
mutators. The observed counts of non-synonymous and synony-
mous mutations in these mutators are not significantly different
than expected by chance (non-synonymous: P=0.30; synonymous:
P=0.43), suggesting that many more mutations are neutral and
that these strains show a general and unbiased increase in
mutation rate. The observed number of intergenic mutations (3) in
the mutator strains is significantly higher than expected by chance,
however (P=0.011), suggesting that at least one of these mutations
has been driven by selection.
Genetic basis of adaptation to ciprofloxacin
Observed changes in ciprofloxacin MIC and in fitness are
attributable to some or all of the mutations identified by WGS. For
example, in the ciprofloxacin-evolved strains, we observed
multiple mutations in the known fluoroquinolone-resistance genes
gyrA, gyrB, and nfxB. Amongst 24 genotypes from populations
evolved in the presence of ciprofloxacin, 20 bore mutations in
nfxB, 9 carried mutations in gyrB, and 4 genotypes bore gyrA
mutations. Each of the gyrA mutations is a known resistance
mutation affecting its quinolone-resistance determining region
(QRDR; [44,45]), with one strain carrying a T83I mutation, two
with D87G, and one with a D87N mutation. The gyrB mutations
were dispersed throughout this gene, with 6 different lesions
amongst the 9 strains (Figure 4). In nfxB, loss of function mutations
would be expected to be prevalent, since inactivation of this
transcriptional repressor results in up-regulation of the MexCD-
OprJ efflux pump (e.g., [46]). Concordant with this expectation, 8
distinct mutations were found in nfxB among the 20 genotypes
bearing mutations (Figure 4). Interestingly, three sites were
mutated in multiple strains (T39P in 3 strains, in a predicted
helix-turn-helix DNA-binding domain; E146K in 5 strains; G180S
in 8 strains), providing further evidence that these mutations are
adaptive.
Additionally, 7 ciprofloxacin-resistant genotypes carried muta-
tions in the gene orfN, 6 being isolated from populations evolved in
scfm+Cip. orfN encodes a predicted glycosyl transferase, and is
necessary for the glycosylation of type A flagellins [47]. 6 of the
orfN mutants carried a single base pair deletion in a poly-G repeat,
leading to the introduction of a premature stop codon. The
predicted mutant protein is truncated after 53 amino acid residues
(vs 338 for the wild-type protein). The seventh orfN mutant carries
a single base-pair deletion in a poly-T repeat, leading to a
truncated protein of 133 residues. The predicted mutant proteins
are truncated before or in the glycosyl transferase domain,
suggesting that the orfN mutations are likely to be loss-of-function
mutations (Figure 4). While this gene has not previously been
associated with fluoroquinolone resistance, this observation of
extensive parallel evolution strongly suggests that orfN mutants
have increased fitness in the presence of ciprofloxacin.
To obtain further evidence for an effect of orfN and other
putative novel resistance mutations on Cip resistance, we surveyed
isolates from evolving populations from early time points and
Figure 3. Numbers of mutations identified in evolved genotypes. Mean number of mutations by treatment, with error bars giving +/21 SE.
In the ‘‘scfm+mucin+Cip’’ treatment, the filled circle represents all evolved genotypes, and the filled diamond represents the ten non-mutator
genotypes.
doi:10.1371/journal.pgen.1002928.g003
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assayed their MICs in the genetic backgrounds in which they
arose. This approach allows us to sample candidate genes
relatively quickly in the context in which they evolved. For orfN
mutants, we sampled single colony isolates from early time points
(days 3–5 of the evolution experiment) from populations where an
orfN mutation was observed at day 8. Early time-point isolates were
sequenced at all genes bearing a SNP at day 8, and clones bearing
only an orfN mutation were selected. In this way, we identified
several apparent single orfN mutants: 2 from population scfm-A5 at
day 3, and 1 from population scfm-D6 at day 5. As expected each
of these putative single mutants showed a 32-fold elevation in
ciprofloxacin MIC in comparison to the ancestral Pa14 genotype,
suggesting that orfN is a novel resistance gene.
While the observation of parallel evolution at nfxB, gyrA, gyrB,
and orfN is indicative of natural selection acting on these genes, 12
of the mutations identified in the non-mutator strains appeared in
only a single isolate each (Figure S5). Such mutations may
represent adaptive mutations of minor effect, or they may be
neutral mutations that are either segregating due to drift or have
hitchhiked alongside other strongly adaptive mutations. In several
cases, MIC analyses suggest a benefit to these mutations arising
through increased levels of antibiotic resistance. Genotypes
containing a single mutation in Pa14_32420 (encoding a putative
oxidoreductase) isolated from an early time point (day 3) showed a
4-fold increase in ciprofloxacin MIC and a SNP in Pa14_46110
(encoding a predicted sodium:solute symporter), which was the
third mutation to arise in the population, had an 8-fold higher
MIC than did genotypes carrying only the first two mutations
(which occurred in nfxB and Pa14_23430). Thus, the evolution of
quinolone resistance appears to have involved both highly parallel
changes, as well as mutations specific to individual experimental
populations.
Previously, Breidenstein et al. [48] conducted a screen of
transposable-element insertions for novel ciprofloxacin resistance
determinants. Interestingly, there is almost no overlap between
between the 114 genes identified by Breidenstein et al. and the 44
genes bearing SNPs in this study. nfxB and mutS mutants were
isolated in both experiments, but no other gene was found as a
potential resistance factor in both studies. In addition, Breidenstein
et al. identified a number of phage-related or phage-derived genes
as resistance modifiers, and we found a non-coding mutation in a
different cluster of phage-related genes (at position 1927375 of the
Pa14 genome). The difference between these two studies is likely
due to the different mechanisms that lead to resistance mutations
in the two studies: transposon insertions were used by Breidenstein
et al. paper, and spontaneous point mutations and indels in the
current study. Importantly, the lack of overlap between the two
studies is an indication that many genes potentially contribute to
fluoroquinolone resistance in P. aeruginosa, and suggests that in
general multiple approaches should be taken in the identification
of genes underlying phenotypes of interest. Experimental evolu-
tionary approaches, such as the one adopted here, differ from
traditional mutational studies in that selection acts as an extra sieve
that will weed out slow-growing mutants that, while they confer
resistance, are out-competed on the way to fixation by other
mutations conferring higher fitness (see [17,18] for discussions of
the use of experimental evolution as a tool for mutation discovery).
While this effect of natural selection will likely eliminate some
mutations of interest (especially for understanding underlying
biological pathways), mutations observed under selection may be
more clinically relevant due to their relatively high fitness.
What explains the prevalence of clinical resistance
mutations?
Surveys of clinical samples of Pseudomonas aeruginosa often
uncover a handful of genes with major effects on fluoroquinolone
resistance. Most commonly, these genes are gyrA and gyrB, which
encode the subunits of the fluoroquinolone target DNA gyrase,
and the efflux pump regulators nfxB and mexR (e.g., [44,46,49,50]).
Given that mutational surveys have revealed many other genes
Figure 4. Locations of mutations in the ciprofloxacin resistance proteins nfxB, orfN, gyrB, and in the putatively mucin-adaptive
protein morA. ‘‘S’’: location of a single nucleotide polymorphism; ‘‘F’’: frameshift; ‘‘I’’: in-frame insertion; ‘‘D’’: in-frame deletion.
doi:10.1371/journal.pgen.1002928.g004
Genomics of Adaptation in P. aeruginosa
PLOS Genetics | www.plosgenetics.org 6 September 2012 | Volume 8 | Issue 9 | e1002928
that can confer resistance to fluoroquinolones, why is it that these
four genes are repeatedly recovered from clinical samples?
One possibility is that these genes enjoy a large fitness advantage
in the presence of antibiotic because they confer large increases in
MIC. To test this prediction, we asked to what extent the presence
or absence of mutations in classical resistance genes is a predictor
of the level of ciprofloxacin resistance. As described above, many
of the ciprofloxacin-evolved strains in this study bore mutations in
one or several of gyrA, gyrB, and nfxB, although no mexR mutants
were isolated. A linear model including selection medium
(scfm+Cip or scfm+mucin+Cip) and presence or absence of
mutations in gyrA, gyrB, and nfxB explains ,87% of variation in
MIC between genotypes (Table 2, Figure 5A, 5B). Under this
model, mutations in nfxB, gyrA, and gyrB are associated with
average MIC increases of 25.3, 3.2, and 10.9-fold, respectively.
Thus, a substantial fraction of variation in the level of resistance is
attributable to mutations in classical resistance genes. It should be
noted that the genotypes indicated in Figure 5 are not exhaustive –
for example, a given nfxB mutant on Figure 5 will also carry at
least one additional mutation. Thus, variation within a genotype
class (for example, the nfxB mutants) is attributable to these
additional mutations.
An alternative, and not mutually exclusive, possibility is that
these mutations pay little cost of resistance in the absence of
antibiotic. Cost-free resistance may arise because the mutations
themselves are not costly or because second-site mutations rapidly
evolve that compensate for whatever cost they do incur. We tested
this prediction by examining the fitness of strains bearing (or not)
mutations in classical resistance genes in the absence of
ciprofloxacin and found little relationship between genotype and
fitness (Table 3, Figure 5C, 5D; see also Figure S6). Notably, only
strains carrying nfxB mutations from the scfm+Cip environment
show an increase in fitness in the absence of antibiotic (Table 3)
and none of the gyrA, gyrB, or nfxB mutants from the
scfm+mucin+Cip environment were significantly different from
the ancestor. This result may be surprising, given that single
mutations in gyrA and nfxB are typically costly [16,51,52] but we
note that none of the strains examined here carried only a gyrA or
nfxB mutation; all were at least double mutants. This result
suggests that fitness in the absence of antibiotic appears to be
determined or modulated by mutations in genes other than nfxB,
gyrA, and gyrB. Thus cost-free resistance probably arises through
second-site mutations that compensate for the costs incurred by
these classical resistance genes, consistent with the results of
previous studies [13,53–56]. It is notable that these compensatory
mutations would have to have arisen very quickly alongside or
soon after resistance had evolved for them to be observed in the
short time frame of our experiment.
What sorts of second-site mutations might be involved in
compensating for the fitness costs of nfxB, gyrA, or gyrB resistance
mutations? Our genome-wide survey of mutations provides some
insight. We have found a wide range of mutations amongst the
Cip-resistant genotypes sequenced in this study. These include
mutations in the gene nusA encoding an elongation factor, a
putative kinase encoding gene Pa14_28895, and ate1, which
encodes an arginyl-trNA-protein transferase (see Table S2 for a
full list).
While genotype at classical resistance genes predicts MIC (but
generally not fitness), we find no evidence that the raw number of
mutations present in a lineage predicts either MIC or fitness in the
absence of antibiotic (data not shown). These data are consistent
with a model in which classical resistance genes make particularly
large contributions to MIC that can mask the smaller effects of
other resistance mutations, even if these latter mutations occur first
or provide additional increases to MIC or fitness.
Taken together, these results suggest that the prevalence of
classical fluoroquinolone resistance mutations such as those in gyrA
and nfxB in clinical isolates is due to the combination of high levels
of resistance and apparent lack of costs due to second site
mutations. These results are of clinical importance because they
suggest that attempts to combat resistance in patient populations
by stopping the use of the offending antibiotic in the hopes that
drug sensitive types will replace resistant ones will often fail (e.g.,
[57]). Epidemiological evidence on the effectiveness of this strategy
at controlling resistance is both limited and mixed [6,58]: reducing
the use of antibiotics often leads to a reduction in the frequency of
resistant strains, but it rarely succeeds in eliminating them
altogether [4,5]. Our results suggest that the mechanistic reason
for this failure is not that resistance mutations are cost-free but,
rather, that their costs are rapidly compensated for by a diverse
array of mutations elsewhere in the genome.
Genetic basis of adaptation to a CF–like culture
environment
Our genomic analysis also sheds light on the genetic pathways
to adaptation in CF-like conditions. Strains evolved in the most
CF-like environment, scfm+mucin, often contained mutations in
genes implicated in cyclic-di-GMP signalling. Elevated levels of
intracellular cyclic-di-GMP are thought to induce a shift from a
motile, planktonic lifestyle to a non-motile biofilm state in a variety
of bacteria [27–29]. We suspect that increases in diguanylate
cyclase activity may be adaptive in the presence of mucin, which
encourages biofilm growth. Consistent with this hypothesis, three
genes with putative roles in diguanylate cyclase signalling were
repeatedly found mutated in the evolved strains. 9 of 24
populations (8 without ciprofloxacin, 1 with ciprofloxacin)
contained isolates bearing mutations in the morA gene (Figure 4).
morA encodes a predicted membrane-localized diguanylate cyclase,
and serves as a negative regulator of flagellum formation [59]. In
P. aeruginosa, expression of morA is required for the switch from
wild-type colony morphology to the small-colony variant mor-
phology [27], which is associated with biofilm formation in CF
infections [25]. 7 distinct morA mutations – all missense point
mutations - were identified in our evolved strains (Figure 4). Two
scfm+mucin-evolved strains bore mutations in wspF, which
encodes a regulator of the diguanylate cyclase WspR, with wspF
loss-of-function mutants showing increased biofilm formation [28]
and wrinkly colony morphologies in Pseudomonas fluorescens [60].
One of the wspF alleles recovered in this study is likely a loss-of-
function mutation, since it encodes an early frame-shift. The
second allele is a single in-frame codon deletion whose effects we
cannot predict. Finally, the gene Pa14_56280, encoding another
predicted diguanylate cyclase, was found to be mutated in two
further scfm+mucin adapted strains.
Table 2. Effects of medium and genotype on ciprofloxacin
MIC.
Factor Estimate ( log2(MIC) ) Std. Error t P-value
Intercept 2.1422 0.32 6.63 8.7861028
Medium (mucin) 20.892 0.41 22.15 0.038
gyrA 1.66 0.78 2.13 0.04
gyrB 3.44 0.49 6.98 2.9861028
nfxB 4.66 0.47 9.96 5.06610212
doi:10.1371/journal.pgen.1002928.t002
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In light of the role of cyclic-di-GMP signalling in biofilm
formation [27–29], we predicted that our putative cyclic-di-GMP
signalling mutants should show increased aggregation and biofilm
formation. To test this prediction, we examined colony morphol-
ogy on Coomassie blue/Congo red agar plates, which is a sensitive
indicator of aggregation (e.g., [61–63]). Isolates bearing mutations
in morA, wspF, or Pa14_56280 showed wrinkly, red morphologies
in comparison to the ancestral Pa14 strain (Figure 6A–6E),
consistent with increased aggregation and biofilm formation.
Genotypes bearing mutations in different genes, and even different
mutations in the same gene (e.g. for morA, compare Figure 6B and
6C), showed different colony morphologies, suggestive of different
effects on the level, timing, and/or localization of aggregation
signals, presumably cyclic-di-GMP.
The frequency with which cyclic-di-GMP signalling genes are
mutated in our mucin evolved strains – with apparent conse-
quences for aggregation and biofilm formation – strongly suggests
Figure 5. Mutations in known resistance genes are strong predictors of ciprofloxacin resistance, but not fitness. Fold-increase in MIC
(A and B), or relative fitness (C and D), for genotypes bearing the given mutations, with genotypes evolved in scfm (A and C) or scfm+mucin (B and D).
doi:10.1371/journal.pgen.1002928.g005
Table 3. Effects of genotype on fitness in the absence of
antibiotic.
scfm scfm+mucin
Factor Estimate (s) P-value Estimate (s) P-value
Intercept 20.036 0.41 0.018 0.74
gyrA NA NA 20.18 0.15
gyrB 20.14 0.12 20.076 0.54
nfxB 0.22 0.004 20.066 0.64
doi:10.1371/journal.pgen.1002928.t003
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a shared mode of adaptation towards a novel in vitro environment.
This finding parallels data from clinical isolates of P. aeruginosa:
Long-term adaptation of P. aeruginosa to the CF lung is
characterized in part by extensive biofilm formation (e.g.,
[26,64]) and the switch to a largely non-motile lifestyle is likely
mediated by cyclic-di-GMP signalling (e.g., [25,65]). Notably,
wspF mutations have previously been documented in CF isolates
(e.g., [10]); the current data suggest several other possible
mediators of biofilm formation in clinical isolates.
Unexpectedly, all strains bearing mutations in the quinolone-
resistance gene nfxB showed smooth colony morphologies
(Figure 6F), a phenotype typically associated with impaired biofilm
production (e.g., [61–63]). This observation suggests an effect of
nfxB on biofilm formation and/or extracellular matrix production,
which to our knowledge has not been previously reported.
Parallel evolution
The extent of parallel evolution during adaptation is of interest
for a variety of reasons; evolution is in principle predictable (or not)
to the extent that independent populations adapt to similar
environments via the same (or different) mutations. The observa-
tion of substantial parallel evolution is also used as an indicator of
strong positive selection. Previous experimental evolution studies
have documented varying degrees of parallel evolution at both the
phenotypic and genotypic levels [66–73]. We have already noted
parallel evolution in response to ciprofloxacin and to mucin in our
study, with multiple lineages bearing mutations in the quinolone
resistance genes gyrA, gyrB, nfxB, orfN, and in the apparently mucin-
adaptive genes morA, Pa14_56280, and wspF. These observations
provide strong evidence that these mutations are beneficial.
How prevalent is parallel evolution in our study? To answer this
we used the Jaccard index (J) to quantify the extent of within- and
between-environment genic parallel evolution. For a given pair of
evolved genotypes, J ranges from 0 to 1, with 0 indicating no
parallel evolution and 1 indicating identity (see Materials and
Methods for further details). We calculated the average Jaccard
index J for within- and between-environment comparisons,
excluding genotypes with no SNPs, as well as mutS mutator strains
(Figure S7). Within environments, J was highest for the
scfm+mucin genotypes, due to the high frequency of morA
mutations in this environment. J was intermediate for the
scfm+Cip and scfm+mucin+Cip genotypes, reflecting parallel
evolution at a handful of genes combined with a number of
lineage-specific mutations. Between-environments, J was 0, except
for between the two ciprofloxacin treatments, indicative of some
shared mechanisms of resistance. We rarely saw the exact same
mutation evolving in parallel selection lines, suggesting that the
bulk of parallel evolution in our experiment is through de novo
mutations rather than the selection of rare, pre-existing variants.
For the few cases where the same mutation was observed in
multiple lineages, however, we note that the current study design
cannot formally distinguish between these two alternatives since
our experimental populations were started from a common
founding culture.
We suspect that several different factors contribute to differ-
ences in the propensity for parallel evolution at different genes.
Chevin et al. [74], analyzing an explicitly genomic model of trait
evolution, show that the probability of parallel evolution at a given
locus can depend on the locus specific mutation rate, the
probability of a mutation being beneficial, and the probability of
Figure 6. Variation in colony morphology. Isolates were grown on 1% tryptone plates containing Congo red and Coomassie blue. (A) Ancestral
Pa14; (B) strain smA1 carrying a single mutation in morA (H975Y); (C) strain smA2 carrying a different mutation in morA (L1155Q); (D) strain smD6
bearing three mutations, including one in wspF (an out-of-frame deletion); (E) strain smC3 bearing a single mutation in Pa14_56280 (M204I); (F) strain
scfmB5 carrying a single mutation in nfxB (G180S).
doi:10.1371/journal.pgen.1002928.g006
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a mutation going to fixation. For some loci, e.g. nfxB, loss-of-
function mutations are likely to be beneficial, and so the
probability of a mutation being beneficial will be quite high (see
[73] for a similar example). For other loci, such as gyrA, the
probability of fixation for beneficial mutations may be high due to
their large effects on MIC. Finally, in the case of orfN, where a
slippage mutational mechanism is implicated by the observation of
single base deletions in repeat regions, both the mutation rate and
the probability of a mutation being beneficial are likely to be
elevated. Thus, different genes may undergo parallel evolution for
rather different reasons.
Summary and conclusions
We have studied the genomic basis of adaptation to CF-like
culture conditions and to ciprofloxacin in experimentally evolved
isolates of the opportunistic pathogen P. aeruginosa. Adaptation did
occur to the most CF-like conditions and to the presence of
ciprofloxacin, although our evolving populations are likely highly
polymorphic. We observed parallel evolution at a handful of
antibiotic resistance genes (gyrA, gyrB, nfxB, and orfN), as well as at
putative cyclic-di-GMP signalling genes in the mucin environ-
ment. While the level of antibiotic resistance was determined
largely by known resistance genes, fitness in the absence of
antibiotic was not, such that there was no overall relationship
between resistance and its associated costs.
These findings have several implications for understanding
antibiotic resistance and pathogen evolution. First, we have
identified a suite of novel ciprofloxacin resistance mutations.
Our evolved antibiotic resistant isolates harbour mutations in 12
genes not previously implicated in fluoroquinolone resistance, and
initial assays are consistent with effects on ciprofloxacin MIC for 3
of these genes (orfN, Pa14_46110, and Pa14_32420). Thus,
experimental evolution, coupled with WGS, represents a powerful
approach to identifying novel genes of interest.
Second, we find that the costs of resistance are not systemat-
ically determined by the same mutations that account for most of
the variation in level of resistance (i.e., mutations in gyrA, gyrB, and
nfxB). This finding suggests that whatever costs are associated with
single resistance mutations are easily remediated by mutations at
other loci. Moreover, these results suggest that the prevalence of
these resistance mutations in clinical isolates are likely the result
both of the high levels of resistance they confer and the rapid
compensation of costs by second-site mutations.
Third, the finding of multiple cyclic-di-GMP mutations in the
mucin environment underscores the importance of GMP-mediat-
ed biofilm formation in viscous environments, such as the CF lung.
Finally, our findings suggest that pathogen evolution has a
partially repeatable genomic basis, insofar as some genes are
repeatedly mutated in multiple replicate populations, while others
are not. This observation has important implications for under-
standing pathogen evolution. Those genes that show highly
parallel evolution may be particularly important in their influence
on key adaptive traits governing infection or resistance to
antibiotics. However, genes that are mutated only rarely are not
necessarily unimportant: they often appear to have important
phenotypic consequences, such as compensating for costs of
resistance, and so cannot be ignored. In designing novel medical
interventions, therefore, our results suggest that we would do well
to focus attention first on these common targets of adaptation to
the lung environment, while not losing sight of the potential
importance of rare and sometimes idiosyncratic mutations that
nevertheless play a major role in determining the overall fitness of
the pathogen.
Materials and Methods
Experimental evolution
A single colony of P. aeruginosa strain Pa14 was grown overnight
in minimal medium (NH4Cl 1 g/L, KH2PO4 3 g/L, NaCl 0.5 g/
L, Na2HPO4 6.8 g/L; supplemented with CaCl2 15 mg/L,
MgSO4 0.5 g/L; 0.8% dextrose as a carbon source). Forty-eight
populations were founded from this progenitor by adding 25 mL
overnight culture to 1.5 mL of fresh medium (media described
below). An aliquot of progenitor was frozen at 280uC in glycerol.
Populations were grown on an orbital shaker (150 rpm) at 37uC
for 24 hours in 24-well plates. After 24 hours, each population was
serially propagated by transferring 25 mL of overnight culture to
1.5 mL of fresh medium. Overnight cultures were frozen at
280uC in glycerol. Seven such transfers were conducted in total,
such that approximately 50 generations of evolution occurred
(,5.9/day for 8 days).
Four selection environments were used, consisting of two
different media with or without antibiotic. The media were
chosen so as to examine the effects of CF sputum nutrition and
viscosity on the evolution of antibiotic resistance in P. aeruginosa.
Synthetic CF sputum (scfm) was prepared as described by [30]). In
order to manipulate viscosity, we added 10 g/L porcine mucin
(Sigma) to synthetic CF sputum (scfm+mucin)[32,33]. For
antibiotic treated populations, we used 1 mg/mL ciprofloxacin to
mimic the concentration typically found in the sputum of CF
patients [31].
Phenotypic analyses
For each evolved population, or for pure genotypes isolated
from each population, level of resistance was assayed as the
minimal inhibitory concentration (MIC) of ciprofloxacin. Over-
night cultures were grown in Mueller-Hinton broth (MHB;
Sigma), of which 5 mL was inoculated into 195 mL of fresh
MHB with varying concentrations of ciprofloxacin in 96 well
plates. MIC of the ancestor, i.e., the concentration at which
growth was inhibited by 90%, was 0.05 mg/mL. For each evolved
strain, we assayed growth at 0x, 0.5x, 1x, 2x, 4x, 8x, 16x, 32x, 64x,
128x, 192x, and 256x the ancestral MIC.
Fitness of each evolved population or genotype was assayed
using a competitive fitness assay against a lacZ marked ancestral
strain. Independent assays verified that the lacZ-marked strain did
not bear a fitness cost in competitions with unmarked Pa14. Both
competitors were grown for 24 hours in the competition medium.
At time 0, 12.5 mL of marked ancestor and 12.5 mL of evolved
strain were inoculated into 1.5 mL of fresh medium in a 24-well
plate, and an aliquot was frozen at 280uC in glycerol. Following
24 hours of growth at 37uC at 150 rpm, a final aliquot was frozen
at 280uC in glycerol. Serial dilutions of initial and final aliquots
were grown on solid minimal media+X-gal, allowing us to
determine the numbers of blue (ancestral) and white (evolved)
individuals at the beginning and end of the competition. The
selection coefficient s was calculated as:
(ln½whitefinal=whiteinitial  ln½bluefinal=blueinitial)
=# generations
Relative fitness w was then calculcated as 1+s, where the units for
both w and s are in per generation.
Colony morphology was assayed according to [61]. Briefly,
10 mL of culture grown overnight in LB were spotted in triplicate
onto tryptone plates (10 g/L) supplemented with 20 mg/ml
Coomassie blue and 40 mg/ml Congo red. Plates were grown
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for 4 days at room temperature, after which digital photos were
taken.
Whole-genome sequencing and analysis
For whole-genome sequencing, a single colony was picked from
each evolved population, as well as for the ancestral Pa14
genotype. For each genotype, genomic DNA was extracted from
an overnight culture using the Promega Wizard Genomic DNA
Purification kit. 75-bp paired-end Illumina sequencing was
performed by the Michael Smith Genome Sciences Centre, using
DNA barcodes to sequence 10–12 isolates per lane. Mean
coverage across all 49 genotypes was 55.5-fold at a quality score
of 20 (range: 31.8–85.4).
We performed a pair-end mapping of reads on the Pa14
reference genome number NC_008463.1 using novoalign (http://
novocraft.com/main/index.php). We used samtools [75] to call
snps/indels, and filtered the resulting calls using the provided
samtools.pl script, changing the window size for snps around indels
at 5 base pairs, removing the limit on number of reads spanning a
snp/indel position, and leaving the remaining parameters at their
default values. We further filtered calls with quality scores below
60 for indels, and 20 for snps. To annotate the remaining snps/
indels with respect to the reference genome, we used snpEff
(http://snpeff.sourceforge.net/). We found results to be robust to
performing a pre-mapping clipping of reads based on quality
across cycles using FastQC (http://www.bioinformatics.bbsrc.ac.
uk/projects/fastqc/), and to performing local multiple sequence
re-alignment around indels using the Genome Analysis ToolKit
[76]. We also used the BRESEQ [38] pipeline as a further
validation, and for its insertion/deletions detection capabilities.
Following removal of common assembly errors using custom perl
scripts, a subset of SNPs was verified by Sanger sequencing of
polymerase chain reaction (PCR) amplicons. For each of 31mutations
(out of 98 mutations identified in the 48 evolved strains), we amplified
a 500–700 bp PCR product containing the putative SNP, and directly
sequenced the PCR products (Genome Quebec, Montreal). All 31
mutations that we interrogated were successfully verified.
We used a randomization approach to determine the probabil-
ity of observing by chance the distribution of non-synonymous,
synonymous, and intergenic point mutations. This analysis was
performed separately for putative mutator strains (two mutS
mutants) and for putative non-mutator strains (the remaining 46
strains). 10 000 sets of point mutations were generated at random
from the Pa14 genome sequence, maintaining the observed
numbers of transitions and transversions (mutators: 30 transitions
and 11 transversions; non-muators: 26 transitions and 0 transver-
sions), and SNP effects were predicted using snpEff. Mean
numbers of non-synonymous, synonymous, and intergenic muta-
tions, as well as the 2.5% and 97.5% quantiles of the random
distribution, were calculated in R [77].
Parallel evolution
The extent of parallel evolution was quantified using the Jaccard
Index J. Given two sets G1 and G2 that list mutation-bearing genes
found in genotypes 1 and 2, respectively,
J(G1,G2)~
DG1\G2D
DG1|G2D
That is, J is the number of genes mutated in both strains divided
by the total number of genes mutated in genotype 1 or in genotype
2. J ranges from 0 to 1, with 1 indicating identical genotypes and 0
indicating no shared mutations.
J was calculated for all possible pairs of different genotypes
amongst the 46 non-mutator strains. The average Jaccard Index J
was calculated within a treatment group as the mean J for all pairs
of strains, where both strains were evolved under the same
treatment. Similarly, J was calculated between treatments A and B
as the mean J for all pairs of strains, where one strain was evolved
under treatment A and the second strain was evolved under
treatment B.
Supporting Information
Figure S1 No relationship between pure genotype fitness and
population fitness. Each panel gives a dashed 1:1 line, and a solid
regression line.
(JPG)
Figure S2 Pure genotype MIC is predicted by population MIC
in scfm+mucin, but not scfm. Each panel gives a dashed 1:1 line,
and a solid regression line.
(JPG)
Figure S3 Genomic locations of mutations identified by whole-
genome sequencing. Mutations found only in putative mutator
strains (mutS mutants) are not shown.
(PNG)
Figure S4 Expected and observed distributions of non-synony-
mous, synonymous, and intergenic mutations. Bar plots show the
expected mean and 2.5% and 97.5% quantiles (error bars) for
randomly generated mutations, with observed data represented by
solid black points. (A) Non-mutator strains only. (B) Mutator
strains only.
(JPG)
Figure S5 Site-frequency spectrum of mutations identified in
non-mutator evolved strains.
(JPG)
Figure S6 Higher resistance does not correlate with greater costs
of adaptation. No correlation between MIC and fitness in the
absence of antibiotic in scfm or in scfm+mucin. Single gentoype
data are given in the top two panels, and population data are given
in the bottom two panels.
(JPG)
Figure S7 Parallel evolution within and between treatements.
Parallel evolution was quantified as the average Jaccard index.
Values are given within treatments (circles) or between treatments
(lines).
(JPG)
Table S1 Mutations detected by Illumina sequencing of evolved
genotypes. Strain names give the selection medium as scfm or sm
(scfm+mucin). Strain names ending in 1–3 were evolved in the
absence of Cip, while those ending in 4–6 were evolved in the
presence of Cip. Putative mutator strains are highlighted in red.
(XLS)
Table S2 Mutations with possible compensatory effects on
classical resistance genes. Mutations found to co-occur with known
resistance mutations, that may reduce or eliminate costs associated
with Cip resistance.
(XLS)
Acknowledgments
We thank Jeremy Dettman, Thien-Fah Mah, Marvin Whiteley, Kelli
Palmer, and three anonymous reviewers for helpful comments and
discussion of this work.
Genomics of Adaptation in P. aeruginosa
PLOS Genetics | www.plosgenetics.org 11 September 2012 | Volume 8 | Issue 9 | e1002928
Author Contributions
Conceived and designed the experiments: AW RK NR. Performed the
experiments: AW NR. Analyzed the data: AW NR RK. Contributed
reagents/materials/analysis tools: AW NR RK. Wrote the paper: AW NR
RK.
References
1. Pasteur L (1878) La Theorie des Germes. Comptes Rendus l’Academie des
Sciences 86: 1037–1043.
2. Brown SA, Palmer KL, Whiteley M (2008) Revisiting the host as a growth
medium. Nat Rev Microbiol 6: 657–666.
3. Garber ED (1960) The host as a growth medium. Ann NY Acad Sci 88: 1187–
1194.
4. Andersson DI (2003) Persistence of antibiotic resistant bacteria. Curr Opin
Microbiol l6: 452–456.
5. Salyers AA, Ama´bile-Cuevas CF (1997) Why are antibiotic resistance genes so
resistant to elimination? Antimicrob Agents Chemother 41: 2321–2325.
6. Livermore DM (2004) The need for new antibiotics. Clin Microbiol Infect 10
Suppl 4: 1–9.
7. Ping J, Keleta L, Forbes NE, Dankar S, Stecho W, et al. (2011) Genomic and
Protein Structural Maps of Adaptive Evolution of Human Influenza A Virus to
Increased Virulence in the Mouse. PLoS ONE 6: e21740. doi:10.1371/
journal.pone.0021740.
8. Holmes EC, Zhang LQ, Simmonds P, Ludlam CA, Brown AJ (1992)
Convergent and divergent sequence evolution in the surface envelope
glycoprotein of human immunodeficiency virus type 1 within a single infected
patient. Proc Natl Acad Sci USA 89: 4835–4839.
9. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, et al. (2007)
Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by
whole-genome sequencing. Proc Natl Acad Sci USA 104: 9451–9456.
10. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, et al. (2006)
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis
patients. Proc Natl Acad Sci USA 103: 8487–8492.
11. Elena SF, Lenski RE (2003) Evolution experiments with microorganisms: the
dynamics and genetic bases of adaptation. Nat Rev Genet 4: 457–469.
12. Buckling A, Craig Maclean R, Brockhurst MA, Colegrave N (2009) The Beagle
in a bottle. Nature 457: 824–829.
13. Hall AR, MacLean RC (2011) Epistasis buffers the fitness effects of rifampicin-
resistance mutations in Pseudomonas aeruginosa. Evolution 65: 2370–2379
14. Kassen R (2009) Toward a general theory of adaptive radiation: insights from
microbial experimental evolution. Ann NY Acad Sci 1168: 3–22.
15. Perron GG, Lee AEG, Wang Y, Huang WE, Barraclough TG (2011) Bacterial
recombination promotes the evolution of multi-drug-resistance in functionally
diverse populations. Proc Biol Sci 279:1477–1484.
16. Kugelberg E, Lo¨fmark S, Wretlind B, Andersson DI (2005) Reduction of the
fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob
Chemother 55: 22–30.
17. Counago R, Chen S, Shamoo Y (2006) In vivo molecular Evolution Reveals
Biophysical Origins of Organismal Fitness. Mol Cell 22: 441–449.
18. Marx CJ (2011) Evolution as an experimental tool in microbiology: ‘Bacterium,
improve thyself!’. Environ Microbiol Rep 3: 12–14.
19. Brockhurst MA, Colegrave N, Rozen DE (2011) Next-generation sequencing as
a tool to study microbial evolution. Mol Ecol 20: 972–980.
20. Silby MW, Winstanley C, Godfrey SAC, Levy SB, Jackson RW (2011)
Pseudomonas genomes: diverse and adaptable. FEMS Microbiol Lett 35: 652–
680.
21. Stephenson A (2008) Canadian Cystic Fibrosis Patient Data Registry Report
2008. Toronto.
22. Huse HK, Kwon T, Zlosnik JEA, Speert DP, Marcotte EM, et al. (2010) Parallel
evolution in Pseudomonas aeruginosa over 39,000 generations in vivo. mBio 1:
e00199–10.
23. Wong A, Kassen R (2011) Parallel evolution and local differentiation in
quinolone resistance in Pseudomonas aeruginosa. Microbiology 157: 937–944.
24. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N (2010) Genetic
adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with
cystic fibrosis: strong and weak mutators with heterogeneous genetic back-
grounds emerge in mucA and/or lasR mutants. Microbiology 156: 1108–1119.
25. Starkey M, Hickman JH, Ma L, Zhang N, De Long S, et al. (2009) Pseudomonas
aeruginosa rugose small-colony variants have adaptations that likely promote
persistence in the cystic fibrosis lung. J Bacteriol 191: 3492–3503.
26. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, et al. (2002) Effects of
reduced mucus oxygen concentration in airway Pseudomonas infections of cystic
fibrosis patients. J Clin Invest 109: 317–325.
27. Meissner A, Wild V, Simm R, Rohde M, Erck C, et al. (2007) Pseudomonas
aeruginosa cupA-encoded fimbriae expression is regulated by a GGDEF and EAL
domain-dependent modulation of the intracellular level of cyclic diguanylate.
Environ Microbiol 9: 2475–2485.
28. Hickman JW, Tifrea DF, Harwood CS (2005) A chemosensory system that
regulates biofilm formation through modulation of cyclic diguanylate levels. Proc
Natl Acad Sci USA 102: 14422–14427.
29. Wolfe AJ, Visick KL (2008) Get the message out: cyclic-Di-GMP regulates
multiple levels of flagellum-based motility. J Bacteriol 190: 463–475.
30. Palmer KL, Aye LM, Whiteley M (2007) Nutritional cues control Pseudomonas
aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 189: 8079–
8087.
31. Pedersen SS, Jensen T, Hvidberg EF (1987) Comparative pharmacokinetics of
ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother
20: 575–583.
32. Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, et al. (2010) Gene
expression of Pseudomonas aeruginosa in a mucin-containing synthetic growth
medium mimicking CF lung sputum. J Med Microbiol: 1089–1100.
33. Sriramulu DD, Lu¨nsdorf H, Lam JS, Ro¨mling U (2005) Microcolony formation:
a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med
Microbiol 54: 667–676.
34. Hassett DJ, Sutton MD, Schurr MJ, Herr AB, Caldwell CC, et al. (2009)
Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic
fibrosis airways. Trends Microbiol 17: 130–138.
35. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, et al. (2008) A
polymicrobial perspective of pulmonary infections exposes an enigmatic
pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 105: 15070–15075.
36. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, et al. (2011)
Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic
infections. Am J Respir Crit Care Med 183: 1674–1679.
37. Smith DR, Quinlan AR, Peckham HE, Makowsky K, Tao W, et al. (2008)
Rapid whole-genome mutational profiling using next-generation sequencing
technologies. Genome Res 18: 1638–1642.
38. Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, et al. (2009) Genome evolution
and adaptation in a long-term experiment with Escherichia coli. Nature 461:
1243–1247.
39. Schaaper RM, Dunn RL (1987) Spectra of spontaneous mutations in Escherichia
coli strains defective in mismatch correction: the nature of in vivo DNA
replication errors. Proc Natl Acad Sci USA 84: 6220–6224.
40. Dettman JR, Rodrigue N, Melnyk AH, Wong A, Bailey SF, et al. (2012)
Evolutionary insight from whole-genome sequencing of experimentally evolved
microbes. Mol Ecol epub Feb. 2012.
41. Desai MM, Fisher DS (2007). Beneficial mutation selection balance and the
effect of linkage on positive selection. Genetics 176: 1759–1798.
42. Schoustra SE, Bataillon T, Gifford DR, Kassen R (2009) The properties of
adaptive walks in evolving populations of fungus. PLoS Biol 7: e1000250.
doi:10.1371/journal.pbio.1000250
43. Lynch M (2010) Evolution of the mutation rate. Trends Genet 26: 345–352.
44. Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-
determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob
Agents Chemother 34: 1271–1272.
45. Yoshida H, Nakamura M, Bogaki M, Nakamura S (1990) Proportion of DNA
gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa.
Antimicrob Agents Chemother 34: 1273–1275.
46. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Che-
mother 56: 20–51.
47. Schirm M, Arora SK, Verma A, Vinogradov E, Thibault P, et al. (2004)
Structural and genetic characterization of glycosylation of type a flagellin in
Pseudomonas aeruginosa. J Bacteriol 186: 2523–2531.
48. Breidenstein EBM, Khaira BK, Wiegand I, Overhage J, Hancock REW (2008)
Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa
mutant library for altered susceptibility. Antimicrob Agents Chemother 52:
4486–4491.
49. Hooper DC (2001) Emerging Mechanisms of Fluoroquinolone Resistance.
Emerg Infect Dis 7: 337–341.
50. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S (1991)
Quinolone resistance-determining region in the DNA gyrase gyrB gene of
Escherichia coli. Antimicrob Agents Chemother 35: 1647–1650.
51. Stickland HG, Davenport PW, Lilley KS, Griffin JL, Welch M (2010) Mutation
of nfxB Causes Global Changes in the Physiology and Metabolism of Pseudomonas
aeruginosa. Journal of Proteome Research: 2957–2967.
52. Bagel S, Hu¨llen V, Wiedemann B, Heisig P (1999) Impact of gyrA and parC
mutations on quinolone resistance, doubling time, and supercoiling degree of
Escherichia coli. Antimicrob Agents Chemother 43: 868–875.
53. Marcusson LL, Frimodt-Møller N, Hughes D (2009) Interplay in the selection of
fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5: e1000541.
doi:10.1371/journal.ppat.1000541.
54. Trindade S, Sousa A, Xavier KB, Dionisio F, Ferreira MG, et al. (2009) Positive
epistasis drives the acquisition of multidrug resistance. PLoS Genet 5: e1000578.
doi:10.1371/journal.pgen.1000578.
55. Rozen DE, McGee L, Levin BR, Klugman KP (2007) Fitness costs of
fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Che-
mother 51: 412–416.
56. Ward H, Perron GG, Maclean RC (2009) The cost of multiple drug resistance in
Pseudomonas aeruginosa. J Evol Biol 22: 997–1003.
Genomics of Adaptation in P. aeruginosa
PLOS Genetics | www.plosgenetics.org 12 September 2012 | Volume 8 | Issue 9 | e1002928
57. Gottesman BS, Carmeli Y, Shitrit P, Chowers M (2009) Impact of quinolone
restriction on resistance patterns of Escherichia coli isolated from urine by culture
in a community setting. Clin Infect Dis 49: 869–875.
58. Barbosa TM, Levy SB (2000) The impact of antibiotic use on resistance
development and persistence. Drug Resist Updat 3: 303–311.
59. Choy W-K, Zhou L, Syn CK-C, Zhang L-H, Swarup S (2004) MorA defines a
new class of regulators affecting flagellar development and biofilm formation in
diverse Pseudomonas species. J Bacteriol 186: 7221–7228.
60. Bantinaki E, Kassen R, Knight CG, Robinson Z, Spiers AJ, et al. (2007)
Adaptive divergence in experimental populations of Pseudomonas fluorescens. III.
Mutational origins of wrinkly spreader diversity. Genetics 176: 441–453.
61. Friedman L, Kolter R (2004) Genes involved in matrix formation in Pseudomonas
aeruginosa PA14 biofilms. Mol Microbiol 51: 675–690.
62. Merritt JH, Ha D-G, Cowles KN, Lu W, Morales DK, et al. (2010) Specific
control of Pseudomonas aeruginosa surface-associated behaviors by two c-di-GMP
diguanylate cyclases. mBio 1: e00183–10.
63. Dietrich LEP, Teal TK, Price-Whelan A, Newman DK (2008) Redox-active
antibiotics control gene expression and community behavior in divergent
bacteria. Science 321: 1203–1206.
64. Govan JR, Deretic V (1996) Microbial pathogenesis in cystic fibrosis: mucoid
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60: 539–574.
65. Malone JG, Jaeger T, Spangler C, Ritz D, Spang A, et al. (2010) YfiBNR
mediates cyclic di-GMP dependent small colony variant formation and
persistence in Pseudomonas aeruginosa. PLoS Pathog 6: e1000804. doi:10.1371/
journal.ppat.1000804.
66. Crozat E, Winkworth C, Gaffe´ J, Hallin PF, Riley MA, et al. (2010) Parallel
genetic and phenotypic evolution of DNA superhelicity in experimental
populations of Escherichia coli. Mol Biol Evol 27: 2113–2128.
67. Woods R, Schneider D, Winkworth CL, Riley MA, Lenski RE (2006) Tests of
parallel molecular evolution in a long-term experiment with Escherichia coli. Proc
Natl Acad Sci USA 103: 9107–9112.
68. Cunningham CW, Jeng K, Husti J, Badgett M, Molineux IJ, et al. (1997) Parallel
molecular evolution of deletions and nonsense mutations in bacteriophage T7.
Mol Biol Evol 14: 113–116.
69. Bull JJ, Badgett MR, Wichman HA, Huelsenbeck JP, Hillis DM, et al. (1997)
Exceptional convergent evolution in a virus. Genetics 147: 1497–1507.
70. Wichman HA, Brown CJ (2010) Experimental evolution of viruses: Microviridae
as a model system. Philos Trans R Soc Lond B Biol Sci 365: 2495–2501.
71. Wichman HA, Millstein J, Bull JJ (2005) Adaptive molecular evolution for
13,000 phage generations: a possible arms race. Genetics 170: 19–31.
72. Rokyta DR, Abdo Z, Wichman HA (2009) The genetics of adaptation for eight
microvirid bacteriophages. J Mol Evol 69: 229–239.
73. Cooper VS, Schneider D, Blot M, Lenski RF (2001) Mechanisms causing rapid
and parallel losses of ribose catabolism in evolving populations of Escherichia coli
B. J Bacteriol 183: 2834–2841.
74. Chevin L-M, Martin G, Lenormand T (2010) Fisher’s Model and the Genomics
of Adaptation: Restricted Pleiotropy, Heterogenous Mutation, and Parallel
Evolution. Evolution 64: 3213–3231.
75. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The sequence
alignment/map format and SAMtools. Bioinformatics 25: 2078–2079.
76. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The
genome analysis toolkit: a MapReduce framework for analyzing next-generation
DNA sequencing data. Genome Res 20: 1297–1303.
77. R Core Development Team (2011) R: A language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
Genomics of Adaptation in P. aeruginosa
PLOS Genetics | www.plosgenetics.org 13 September 2012 | Volume 8 | Issue 9 | e1002928
